Is Lifecore Biomedical Inc. Common Stock a good investment? Lifecore Biomedical Inc. Common Stock (LFCR) is currently trading at 4.39 USD. Market analysts have a consensus price target of 6.83 USD. This suggests a potential upside from current levels.
Earnings Schedule: Lifecore Biomedical Inc. Common Stock is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.82.
No, it does not currently pay a dividend.
Lifecore Biomedical Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -1.27.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Community Discussion